Early research (Phase 1)UnknownNCT06367673What this trial is testingNatural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid LeukemiaWho this might be right forAML, Adult Zhejiang University 24
Early research (Phase 1)Active Not RecruitingNCT06325748What this trial is testingSENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDSWho this might be right forAML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies Senti Biosciences 21
Early research (Phase 1)Looking for participantsNCT05945849What this trial is testingCD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AMLWho this might be right forLeukemia, Myeloid, Acute University of Pennsylvania 16
Early research (Phase 1)Looking for participantsNCT05672147What this trial is testingCD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid LeukemiaWho this might be right forAcute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia+1 more City of Hope Medical Center 27
Early research (Phase 1)Study completedNCT04207190What this trial is testingTalazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid LeukemiaWho this might be right forRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia Roswell Park Cancer Institute 24
Early research (Phase 1)Study completedNCT00002890What this trial is testingMonoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous LeukemiaWho this might be right forLeukemiaMyelodysplastic Syndromes Memorial Sloan Kettering Cancer Center 24
Testing effectiveness (Phase 2)UnknownNCT02944162What this trial is testingCAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AMLWho this might be right forAcute Myelogenous LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia With Maturation+2 more PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Post-approval studies (Phase 4)Study completedNCT03727750What this trial is testingEvaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AMLWho this might be right forECGPharmacokineticsSafety Pfizer 51
Testing effectiveness (Phase 2)Study completedNCT04835519What this trial is testingPhase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid LeukemiaWho this might be right forAcute Myeloid LeukemiaRelapse LeukemiaRefractory Acute Myeloid Leukemia Beijing Boren Hospital 5
Early research (Phase 1)Ended earlyNCT00543972What this trial is testingDose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid LeukemiaWho this might be right forMyeloid Leukemia Sanofi 12
Early research (Phase 1)UnknownNCT02799680What this trial is testingAllogeneic CART-33 for Relapsed/Refractory CD33+ AMLWho this might be right forRelapsed and/or Refractory CD33+ AML The Affiliated Hospital of the Chinese Academy of Military Medical Sciences 12
Very early researchUnknownNCT04156256What this trial is testingCD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic MalignanciesWho this might be right forHematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes+2 more iCell Gene Therapeutics 20
Early research (Phase 1)Ended earlyNCT05654779What this trial is testingCLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid LeukemiaWho this might be right forAcute Myeloid Leukemia Institute of Hematology & Blood Diseases Hospital, China 4
Testing effectiveness (Phase 2)UnknownNCT01864902What this trial is testingTreatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33Who this might be right forRelapsed Adult Myeloid LeukemiaChemotherapy Refractory Adult Myeloid Leukemia Chinese PLA General Hospital 10
Early research (Phase 1)Looking for participantsNCT06419634What this trial is testingStudy of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeWho this might be right forAcute Myeloid LeukemiaMyelodysplastic Syndrome Bristol-Myers Squibb 105
Not applicableApproved For MarketingNCT01869803What this trial is testingGemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic LeukemiaWho this might be right forAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+7 more Wake Forest University Health Sciences
Early research (Phase 1)Looking for participantsNCT07668557What this trial is testingAnti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaWho this might be right forAcute Myeloid Leukemia (AML) iCell Gene Therapeutics 18
Testing effectiveness (Phase 2)Ended earlyNCT05984199What this trial is testingDonor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell TransplantWho this might be right forLeukemia, Myeloid, Acute Vor Biopharma 38
Early research (Phase 1)Ended earlyNCT03516760What this trial is testingDose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid LeukemiaWho this might be right forAcute Myeloid LeukemiaRelapsed AMLRefractory AML AvenCell Europe GmbH 36
Testing effectiveness (Phase 2)Study completedNCT03390296What this trial is testingOX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaWho this might be right forRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia M.D. Anderson Cancer Center 50